EZH2 Codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Ryan, Russell J H ^a,b   Nitta, Mai ^a   Borger, Darrell ^a   Zukerberg, Lawrence R ^a   Ferry, Judith A ^a   Harris, Nancy Lee ^a   Iafrate, A John ^a   Bernstein, Bradley E ^a,b,c   Sohani, Aliyah R ^a   Le, Long Phi ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN; PROTEIN BCL 2; TRANSCRIPTION FACTOR EZH2; DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; MUTANT PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CODON; CONTROLLED STUDY; EXPRESSED SEQUENCE TAG; FOLLICULAR LYMPHOMA; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENOTYPE; GERMINAL CENTER B CELL PHENOTYPE DIFFUSE LARGE B CELL LYMPHOMA; HUMAN; LARGE CELL LYMPHOMA; LOSS OF FUNCTION MUTATION; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; ANIMAL; CELL STRAIN 3T3; FIBROBLAST; GENETICS; GERMINAL CENTER; METABOLISM; MOUSE; MUTATION; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CODON; DNA-BINDING PROTEINS; FIBROBLASTS; GENE REARRANGEMENT; GERMINAL CENTER; HUMANS; LYMPHOMA, B-CELL; MICE; MUTANT PROTEINS; MUTATION; NIH 3T3 CELLS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTION FACTORS;

EID: 83355173202     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028585     Document Type: Article

References (25)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al.eds. (2008) WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed Lyon International Agency for Research on Cancer.
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511 Available:http://www.ncbi.nlm.nih.gov/pubmed/10676951. Accessed 26 Aug 2011.
3. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, et al. (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine 346: 1937-47 Available:http://www.ncbi.nlm.nih.gov/pubmed/12075054.
4. Morin R, Johnson N, Severson T, (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genetics 42: 181-5 Available:http://www.ncbi.nlm.nih.gov/pubmed/20081860. Accessed 26 Aug 2011.
5. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, et al. (2010) Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proceedings of the National Academy of Sciences 107: 20980 Available:http://www.ncbi.nlm.nih.gov/pubmed/21078963. Accessed 26 Aug 2011.
6. Yap D, Chu J, Berg T, Schapira M, Cheng SWG, et al. (2011) Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood 117: 2451 Available:http://bloodjournal.hematologylibrary.org/content/117/8/2451.short. Accessed 14 Jul 2011.
7. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, et al. (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629 Available:http://www.nature.com/nature/journal/v419/n6907/abs/nature01075.html. Accessed 22 Jan 2011.
8. Varambally S, Cao Q, Mani R-S, Shankar S, Wang X, et al. (2008) Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322: 1695-9 Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2684823&tool=pmcentrez&rendertype=abstract. Accessed 30 Jul 2010.
9. Bachmann I, Halvorsen O, Collett K, (2006) EZH2 Expression Is Associated With High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and Breast. Journal of Clinical Oncology 24: 268-73 Available:http://www.ncbi.nlm.nih.gov/pubmed/16330673. Accessed 26 Aug 2011.
10. Wang SA, Wang L, Hochberg EP, Muzikansky A, Harris NL, et al. (2005) Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. American Journal of Surgical Pathology 29: 1490-6 Available:http://www.ncbi.nlm.nih.gov/pubmed/16224216.
11. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, et al. (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103: 275-82 Available:http://www.ncbi.nlm.nih.gov/pubmed/14504078. Accessed 7 Jan 2011.
12. Snuderl M, Kolman OK, Chen Y-B, Hsu JJ, Ackerman AM, et al. (2010) B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. American Journal of Surgical Pathology 34: 327-40 Available:http://www.ncbi.nlm.nih.gov/pubmed/20118770.
13. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, et al. (2010) Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Molecular Medicine 2: 146-58 Available:http://www.ncbi.nlm.nih.gov/pubmed/20432502. Accessed 14 Jul 2011.
14. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, et al. (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476: 298-303 Available:http://www.nature.com/doifinder/10.1038/nature10351. Accessed 24 Aug 2011.
15. Trapnell C, Pachter L, Salzberg SL, (2009) TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25: 1105-11 Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2672628&tool=pmcentrez&rendertype=abstract. Accessed 18 Jul 2011.
16. Interests CF, (2011) Integrative genomics viewer. Genomics 29: 24-26 doi:10.1038/nbt0111-24.
17. Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, et al. (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genetics pp. 1-20 Available:http://www.ncbi.nlm.nih.gov/pubmed/20601953. Accessed 6 Jul 2010.
18. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D, (2002) Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes & Development 16: 2893-905 Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=187479&tool=pmcentrez&rendertype=abstract.
19. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New England Journal of Medicine 350: 2129-2139 Available:http://www.nejm.org/doi/full/10.1056/NEJMoa040938. Accessed 22 Jul 2011.
20. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur Ga, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. New England Journal of Medicine 363: 809-19 Available:http://www.ncbi.nlm.nih.gov/pubmed/20818844.
21. Bödör C, O'Riain C, Wrench D, Matthews J, Iyengar S, et al. (2011) EZH2 Y641 mutations in follicular lymphoma. Leukemia 25: 726-729 Available:http://www.ncbi.nlm.nih.gov/pubmed/21233829. Accessed 26 Aug 2011.
22. Pasqualucci L, Trifonov V, Fabbri G, Ma J, (2011) Analysis of the coding genome of diffuse large B-cell lymphoma. Nature Genetics 43: 830-837 Available:http://www.ncbi.nlm.nih.gov/pubmed/21804550. Accessed 30 Aug 2011.
23. Kang MH, Reynolds CP, (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clinical Cancer Research 15: 1126-32 Available:http://www.ncbi.nlm.nih.gov/pubmed/19228717.
24. Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, et al. (2006) A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. New England Journal of Medicine 354: 2419-2430 Available:http://www.nejm.org/doi/pdf/10.1056/NEJMoa055351. Accessed 2 Apr 2011.
25. Laible G, Wolf A, Dorn R, Reuter G, Nislow C, et al. (1997) Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. The EMBO Journal 16: 3219-32 Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1169939&tool=pmcentrez&rendertype=abstract.